Insider transactions

Frank Torti

CIK 1647805 · President and Vant Chair · last filed 2026-10-02

Frank Torti is a President and Vant Chair who has filed 34 SEC Form 4 insider transactions across 8 companies since 2018. The most recent filing shows the insider had shares withheld for taxes covering $1.5M of ROIV on Oct 2, 2026. Across all open-market trades the lifetime net is −$81.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $519.2M across reported positions. 9 SEC filings were submitted jointly with Roivant Sciences Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$519.17M
Companies
8
Total Filings
34
Lifetime Open-Market Net
-$81.92M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
411 E MAIN STREET
SUITE 205
ASPEN, CO 81611
Related Filers
Roivant Sciences Ltd. — 9 joint filings, latest 2026-07-02
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ROIV President and Vant Chair 13,495,893 $35.95 $485.18M -$82.04M 6 2026-10-02
IMVT Director 1,009,228 $33.68 $33.99M $116.2K 8 2026-04-09
ABUS Director — $4.44 — $0 7 2024-05-24
Sio Gene Therapies Inc. (SIOX) Delisted Director — $0.48 — $0 1 2021-04-19
Immunovant, Inc. (IMVTW) Delisted Director 28,400 — — $0 2 2020-05-18
Sio Gene Therapies Inc. (AXGT) Delisted Director — — — $0 1 2020-04-17
Myovant Sciences Ltd. (MYOV) Delisted Director — $26.98 — $0 2 2019-08-27
Urovant Sciences Ltd. (UROV) Delisted Director — $16.24 — $0 2 2019-07-11

Recent Filings

34 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-10-02 ROIV Tax (F) +40,309 $1.47M EDGAR
2026-07-02 ROIV Tax (F) −40,310 -$1.43M EDGAR
2026-04-09 IMVT Grant (A) +174,189 $0 EDGAR
2026-04-02 ROIV Tax (F) −160,035 -$4.43M EDGAR
2026-02-23 ROIV Mixed — -$70.49M EDGAR
2026-02-20 ROIV Notice (144) −1,600,000 -$44.03M EDGAR
2026-02-19 ROIV Notice (144) −1,400,000 -$38.47M EDGAR
2025-12-29 ROIV Notice (144) −64,891 -$1.46M EDGAR
2025-12-29 ROIV Mixed — $2.48M EDGAR
2025-08-01 ROIV Grant (A) +13,736,547 $0 EDGAR
Showing 1–10 of 34
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.